Facebook Twitter Linkedin



Enrollees in Nigeria, Kenya and Tanzania


Total disbursed loan amount in USD


Number of patient visits to SafeCare facilities per month


Number of active clinics in the SafeCare program


Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots

Apr 17, 2013

Virological failure (VF) has been identified as the earliest, most predictive determinant of HIV-1 antiretroviral treatment (ART) failure. Due to high costs and complexity of virological monitoring, VF assays are rarely performed in resource-limited settings (RLS). Rather, ART failure is determined by clinical monitoring and to a large extent immunological monitoring. This paper describes the development and evaluation of a low-cost, dried blood spot (DBS)-compatible qualitative assay to determine VF, in accordance with current WHO guideline recommendations for therapy-switching in RLS. The described assay is an internally-controlled qualitative real-time PCR targeting the conserved long terminal repeat domain of HIV-1. This assay was applied with HIV-1 subtypes A-H and further evaluated on HIV-1 clinical plasma samples from South Africa (n=191) and Tanzania (n=42). Field evaluation was performed in Uganda using local clinical plasma samples (n=176). Furthermore, assay performance was evaluated for DBS. The described assay is able to identify VF for all major HIV-1 group-M subtypes with equal specificity, and lower detection limit of 1.00E+03 copies/ml for plasma and 5.00E+03 copies/ml for DBS. Comparative testing yielded accurate VF determination for therapy-switching in 89%-96% of samples compared to gold standards. The assay is robust and flexible, allowing for “open platform” applications and producing comparable results to commercial assays. Assay design enables application in laboratories that can accommodate real-time PCR equipment, allowing decentralization of testing to some extent. Compatibility with DBS extends access of sampling and thus access to this test to remote settings.

Click here to read the full article.



Author: Susan C Aitken, Aletta Kliphuis, Michelle Bronze, Carole L. Wallis, Cissy Kityo, Sheila Balinda, Wendy S. Stevens, Nicole Spieker, Tulio de Oliveira, Tobias F. Rinke de Wit and Rob Schuurman

Date: April 2013


On 12 September 2016, OPIC, Calvert Foundation and two private investors announce expansion
PharmAccess and its German consultancy partner GFA have won a 27.3 million Euros tender from the German development bank KfW to improve access to healthcare for low-income pregnant women in 5 regions of Tanzania.
President Felipe Nyuse of Mozambique officially opened the University Clinic


A population-based study
Date: September, 2015

Research findings on Health Insurance Fund supported programs

Date: February, 2015